The Trump administration on Tuesday announced the creation of TrumpRx, a direct-to-consumer website where customers can buy drugs directly. It also announced an agreement with Pfizer for significant price reductions for drugs that will be offered on the new platform.
"This is a critical step forward in our work to improve health care for hardworking, low-income Americans," Trump said. The website is part of a broader administration initiative to implement a most favored nation pricing model in which Americans pay no more for drugs than the lowest prices charged in other wealthy countries.
Pfizer announced that most of its primary care treatments and some select specialty brands will be offered at average savings of 50% and as high as 86%.
“We are proud to join President Trump at the White House to celebrate this landmark agreement that is a win for American patients, a win for American leadership and a win for Pfizer,” CEO Albert Bourla said. “By working closely with the administration, we are lowering costs for patients and enabling greater investment in the U.S. biopharmaceutical ecosystem by ending the days when American families alone carried the global burden of paying for innovation. This is about putting all patients first and ensuring America remains the world’s leading engine of medical breakthroughs.”
Trump hailed Pfizer’s participation.
"I'm thrilled to announce that one of the world's largest pharmaceutical manufacturers and one of the best anywhere in the world, Pfizer, has agreed to offer countless prescription medications at major discounts in the United States, a result of the most favored nation drug pricing order that we established earlier this year," he said.
Responses from pharmaceutical industry organizations were mixed.
“Pharmacy benefit manager share the Trump administration’s goal of reducing prescription drug costs for every patient in America and have repeatedly called on drug companies to lower list prices, which is the most effective and lasting way to deliver a better deal for the American people," the Pharmaceutical Care Management Association said.
However, the National Association of Chain Drug Stores disagreed.
"The president’s announcement reflects the reality that PBM tactics are exploding Americans’ prescription drug costs, and this action is an attempt to strike a blow against the PBMs’ manipulation and self-enrichment in the prescription drug supply chain," said Steven Anderson, the group’s president and CEO.
A senior Trump administration official told ABC News after the announcement that the White House hopes to make the TrumpRx website available in early 2026.
© Arc, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to TMSalesOperations@arc-network.com. For more information visit Asset & Logo Licensing.